CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Certolizumab pegol

Last Updated: September 3, 2009
Result type: Reports
Project Number: SR0175-000
Product Line: Reimbursement Review

Generic Name: Certolizumab pegol

Brand Name: Cimzia

Manufacturer: UCB Pharma Canada Inc.

Therapeutic Area: Arthritis, rheumatoid

Indications: Arthritis, rheumatoid

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 27, 2010

Recommendation Type: Do not list